This page shows you the latest news items in this category. This is page number 15.

Total 219622 results found since Jan 2013.

Complications of autologous breast reconstruction.
Abstract Flap reconstruction techniques are increasingly desired by French's patients and it represents almost half of breast reconstruction indications in 2017. The main reasons of this statistics are the growing concerns of the patients with breast implant of developing BIA-ALCL, as well as their desire of having a more natural reconstruction results without having any foreign bodies. The multiplication of autologous reconstruction techniques, especially microsurgical techniques which has been popularized in the recent years, makes possible to propose a reconstruction to the majority of patients without an impla...
Source: Annales de Chirurgie Plastique et Esthetique - August 2, 2019 Category: Cosmetic Surgery Authors: Meresse T, Chaput B, Grolleau JL, Gangloff D Tags: Ann Chir Plast Esthet Source Type: research

Breast reconstruction in France, observational study of 140,904 cases of mastectomy for breast cancer.
CONCLUSION: The high proportion of women not undergoing breast reconstruction after mastectomy suggests that access to this procedure should be improved. PMID: 31383624 [PubMed - as supplied by publisher]
Source: Annales de Chirurgie Plastique et Esthetique - August 2, 2019 Category: Cosmetic Surgery Authors: Nègre G, Balcaen T, Dast S, Sinna R, Chazard E Tags: Ann Chir Plast Esthet Source Type: research

Review of Scottish Breast Screening Programme announced
Expected to take a year, it will look at current pressures, uptake, and future deliver options Related items fromOnMedica Social media could help raise breast screening take-up Breast cancer age profile younger in non-white women Women over 75 should still be invited for mammography Black and young women have double risk of triple-negative breast cancer NHS England strips Capita of cervical screening contract
Source: OnMedica Latest News - August 2, 2019 Category: UK Health Source Type: news

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
CONCLUSION: These findings suggested somatic BRCA mutation and EGFR-negativity as a potential biomarker for predicting the efficacy of eribulin/olaparib combination therapy. (UMIN000018721). PMID: 31382135 [PubMed - as supplied by publisher]
Source: Translational Oncology - August 2, 2019 Category: Cancer & Oncology Authors: Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K Tags: Transl Oncol Source Type: research

MicroRNA-21 promotes progression of breast cancer via inhibition of mitogen-activated protein kinase10 (MAPK10).
CONCLUSION: MiR-21 promotes the proliferation, migration and invasion and inhibits the apoptosis of breast cancer cells by inhibiting MAPK10. PMID: 31375553 [PubMed - as supplied by publisher]
Source: Bioscience Reports - August 2, 2019 Category: Biomedical Science Authors: Xie Y, Liu Y, Fan X, Zhang L, Li Q, Li S, Wang H, Xiao Y Tags: Biosci Rep Source Type: research

Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant
ConclusionFulvestrant treatment benefited patients with lungw/o liver or nonvisceral metastases. When treating HR ‐positive/HER2‐negative MBC patients with endocrine therapy, it is important to differentiate patients with lung metastases from those with liver metastases.
Source: Cancer Medicine - August 2, 2019 Category: Cancer & Oncology Authors: Min He, Jun ‐Jie Li, Wen‐Jia Zuo, Lei Ji, Yi‐Zhou Jiang, Xi‐Chun Hu, Zhong‐Hua Wang, Zhi‐Ming Shao Tags: ORIGINAL RESEARCH Source Type: research

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.
Abstract 5-ALA fluorescence-guided surgery (FGS) is a major advance in neuro-oncological surgery. So far, Protoporphyrin IX (PpIX)-fluorescence has been observed in about half of cerebral metastases resected with routinely equipped microscopes during 5-ALA FGS. The aim of the present pilot study was to quantify PpIX-induced fluorescence of cerebral metastases with a spectrometer. We hypothesize that non-fluorescing metastases under the operating microscope may have spectrometrically measurable levels of fluorescence. A second aim was to analyze correlations between quantified 5-ALA fluorescence and histology or pr...
Source: Clinical Breast Cancer - August 2, 2019 Category: Cancer & Oncology Authors: Knipps J, Fischer I, Neumann LM, Rapp M, Dibué-Adjei M, Freiin von Saß C, Placke JM, Mijderwijk HJ, Steiger HJ, Sabel M, Cornelius JF, Kamp MA Tags: Clin Exp Metastasis Source Type: research

Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors
Paclitaxel is a common chemotherapy drug associated with the development of chronic paclitaxel-induced peripheral neuropathy (PIPN). PIPN is associated with neuroinflammatory mechanisms in pre-clinical studies. Here, we evaluated for differential gene expression (DGE) in peripheral blood between breast cancer survivors with and without PIPN and for neuroinflammatory (NI) related signaling pathways and whole-transcriptome profiles from other experiments. Pathway impact analysis identified 8 perturbed NI related pathways.
Source: Journal of Neuroimmunology - August 2, 2019 Category: Allergy & Immunology Authors: Christine Miaskowski, Kimberly Topp, Yvette P. Conley, Steven M. Paul, Michelle Melisko, Mark Schumacher, Margaret Chesney, Gary Abrams, Jon D. Levine, Kord M. Kober Source Type: research

Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
CONCLUSIONS.—: Attention must be given to specimen handling to ensure accurate ER, PR, and HER2 biomarker assessment and appropriate management of breast cancer patients. PMID: 31373514 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - August 2, 2019 Category: Laboratory Medicine Authors: Jorns JM Tags: Arch Pathol Lab Med Source Type: research

Bacillus thuringiensis toxins are cytotoxic to cervical cancer (HeLa) but not to breast cancer (MCF7) cells.
Conclusion; Bacillus thuringiensis toxins are able to have a dual cytotoxic action, on insects and on cancer cell lines. PMID: 31376817 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - August 2, 2019 Category: Biotechnology Authors: Mendoza-Almanza G, Rocha-Zavaleta L, Aguilar-Zacarías C, Ayala-Luján J, Olmos J Tags: Curr Pharm Biotechnol Source Type: research

Identification of Prognostic Candidate Genes in Breast Cancer by Integrated Bioinformatic Analysis.
Abstract Breast cancer is one of the most common malignancies. However, the molecular mechanisms underlying its pathogenesis remain to be elucidated. The present study aimed to identify the potential prognostic marker genes associated with the progression of breast cancer. Weighted gene coexpression network analysis was used to construct free-scale gene coexpression networks, evaluate the associations between the gene sets and clinical features, and identify candidate biomarkers. The gene expression profiles of GSE48213 were selected from the Gene Expression Omnibus database. RNA-seq data and clinical information ...
Source: Clinical Genitourinary Cancer - August 2, 2019 Category: Cancer & Oncology Authors: Wang CCN, Li CY, Cai JH, Sheu PC, Tsai JJP, Wu MY, Li CJ, Hou MF Tags: J Clin Med Source Type: research

Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system
ConclusionWhen compared with LNF, MSA results in a reduction of disease-related expenses for the payer in the year following surgery. While MSA is associated with a higher procedural payer cost compared to LNF, payer costs may  offset due to reduction in the expenses after surgery.
Source: Surgical Endoscopy - August 2, 2019 Category: Surgery Source Type: research

Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21
In this study, we have performed a kinome array analysis of ibrutinib treatment in two HER2 overexpressing breast ca ncer cell lines. Our analysis shows that ibrutinib induces changes in nuclear morphology and causes apoptosis via caspase-dependent extrinsic apoptosis pathway with the activation of caspases-8, caspase-3, and cleavage of PARP1. We further show that phosphorylated STAT3Y705 is upregulated and phosphorylated p21T145 is downregulated upon ibrutinib treatment. We propose that STAT3 upregulation is a passive response as a result of induction of DNA damage and downregulation of phosphorylated p21 is promoting cel...
Source: Investigational New Drugs - August 2, 2019 Category: Drugs & Pharmacology Source Type: research

Associations between persistent organic pollutants and risk of breast cancer metastasis.
CONCLUSION: Our study suggests that 2.3.7.8-TCDD and some PCBs contribute to the development of tumor metastasis and other hallmarks of cancer aggressiveness. While these results should be considered with caution, this is the first study to identify such potential risk factors. Larger longitudinal studies are necessary to confirm our results. Clinical Trial Protocol Record: 2013-A00663-42. PMID: 31382183 [PubMed - as supplied by publisher]
Source: Environment International - August 2, 2019 Category: Environmental Health Authors: Koual M, Cano-Sancho G, Bats AS, Tomkiewicz C, Kaddouch-Amar Y, Douay-Hauser N, Ngo C, Bonsang H, Deloménie M, Lecuru F, Le Bizec B, Marchand P, Botton J, Barouki R, Antignac JP, Coumoul X Tags: Environ Int Source Type: research

Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases
ConclusionOur study found that HCQ has very low concentrations in breast milk. It is probably safe for the patients to give breastfeeding during HCQ therapy period.
Source: European Journal of Clinical Pharmacology - August 2, 2019 Category: Drugs & Pharmacology Source Type: research

Single cell study of adipose tissue mediated lipid droplet formation and biochemical alterations in breast cancer cells
Analyst, 2019, Accepted Manuscript DOI: 10.1039/C9AN00816K, PaperChristina Bl ücher, Carolin Zilberfain, Tom Venus, Nick Spindler, Arne Dietrich, Ralph Burkhardt, Sonja Christa Stadler, Irina Estrela-Lopis Obesity is a known risk factor for breast cancer and a negative prognostic factor for cancer recurrence and survival. Several studies demonstrated that aggressive breast tumor cells contain higher numbers... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - August 1, 2019 Category: Chemistry Authors: Christina Bl ücher Source Type: research

Breast, Cervical, and Colorectal Cancer Screening: Patterns Among Women With Medicaid and Commercial Insurance
ConclusionsBreast and cervical cancer screenings remain underutilized among both commercially insured and Medicaid-insured populations, with lower rates among the Medicaid-insured population. However, almost all women had at least one healthcare encounter, suggesting opportunities for better coordinated care.
Source: American Journal of Preventive Medicine - August 1, 2019 Category: International Medicine & Public Health Source Type: research

Deaf Women's Health: Adherence to Breast and Cervical Cancer Screening Recommendations
ConclusionsThis is a call to action for targeted, accessible health promotion interventions for age-eligible Deaf women to increase adherence to cervical cancer screening.
Source: American Journal of Preventive Medicine - August 1, 2019 Category: International Medicine & Public Health Source Type: research

A novel oncogene TRIM63 promotes cell proliferation and migration via activating Wnt/β-catenin signaling pathway in breast cancer
This study was to reveal a correlation between TRIM63 and the development of breast cancer. In this study, we found that the expression of TRIM63 was significantly increased in breast cancer tissues and closely related to pathological differentiation and TNM stage of breast cancer. Overexpression of TRIM63 could significantly promote proliferation and migration of breast cancer cells, while TRIM63 knockdown significantly inhibited the proliferation and migration of breast cancer cells. In addition, TRIM63 could activate Wnt/β-catenin signaling pathway in breast cancer cells. Further study found that TRIM63 could regulate ...
Source: Pathology Research and Practice - August 1, 2019 Category: Pathology Source Type: research

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Conditions:   Ovarian Cancer;   Breast Cancer Intervention:   Drug: Lynparza Sponsor:   University of Texas Southwestern Medical Center Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Conditions:   Ovarian Cancer;   Breast Cancer Intervention:   Drug: Lynparza Sponsor:   University of Texas Southwestern Medical Center Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Conditions:   Ovarian Cancer;   Breast Cancer Intervention:   Drug: Lynparza Sponsor:   University of Texas Southwestern Medical Center Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT
Condition:   Breast Cancer Intervention:   Drug: 99m-Tc-NM-02 Injection Sponsors:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   NanoMab Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
Conditions:   Ovarian Cancer;   Breast Cancer Intervention:   Drug: Lynparza Sponsor:   University of Texas Southwestern Medical Center Recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Conditions:   HER2-positive Breast Cancer;   Metastatic Breast Cancer;   Locally Advanced Breast Cancer;   Unresectable Breast Cancer Interventions:   Drug: Copanlisib;   Drug: Trastuzumab emtansine Sponsor:   Cancer Trials Ireland Not yet recruiting
Source: ClinicalTrials.gov - August 1, 2019 Category: Research Source Type: clinical trials